Wednesday, August 26, 2015 2:14:44 PM
Novo Nordisk to initiate phase 3a development of oral semaglutide, a once-daily oral GLP-1 analogue
Bagsværd, Denmark, 26 August 2015 - Novo Nordisk today announced the decision to initiate a phase 3a programme with oral semaglutide; a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows the encouraging results of the proof–of-concept phase 2 trial announced on 20 February 2015 and the subsequent consultations with regulatory authorities.
Novo Nordisk intends to initiate a global phase 3a programme, named PIONEER, comprising seven trials with approximately 8,000 people with type 2 diabetes. The PIONEER programme will include six safety and efficacy trials and one trial for evaluating the cardio-vascular safety of oral semaglutide. The first trial in the programme is planned for initiation in first quarter of 2016 and will investigate the efficacy and safety of once- daily oral semaglutide doses of 3 mg, 7 mg and 14 mg, compared to once-daily oral anti- diabetic sitagliptin dose of 100 mg. The remaining six trials of the PIONEER programme are all expected to be initiated during 2016.
In order to meet capacity requirements for current and future diabetes care products, including oral semaglutide, Novo Nordisk expects to invest an estimated 2 billion US dollars over the coming five years in two new production facilities; a new production facility for a range of active pharmaceutical ingredients in Clayton, North Carolina, US and a new drug-product facility in Måløv, Denmark. The final design and cost of the new production facilities will be presented for approval by the company’s board of directors in 2016.
“Delivering protein-based medicine like semaglutide in the form of a tablet and producing it on a large scale is a major challenge, and with the announcement today we have reached a significant milestone towards achieving that goal”, said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “We are excited about the opportunities oral semaglutide represents as a new oral anti-diabetic agent to further improve type 2 diabetes treatment”.
Page 2 of 2
About semaglutide
Semaglutide (NN9924) is a new glucagon-like peptide-1 (GLP-1) analogue that can help people with type 2 diabetes achieve substantial lowering of blood glucose with a low risk of hypoglycaemia. In addition, semaglutide induces weight loss by decreasing appetite and food intake. The oral formulation of semaglutide is provided in a tablet formulation with SNAC, an absorption-enhancing excipient included in the Eligen® Carrier Concept. The Eligen® technology is licenced from Emisphere Technologies, Inc.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,700 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
Media:
Katrine Sperling +45 3079 6718 krsp@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com
Novo Nordisk A/S
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 52 / 2015
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: August 26, 2015
NOVO NORDISK A/S
Lars Rebien Sørensen,
Chief Executive Officer
Novo Nordisk A S (NYSE:NVO)
Historical Stock Chart
1 Year : From Aug 2014 to Aug 2015
Click Here for more Novo Nordisk A S Charts.
Novo Nordisk A S (NYSE:NVO)
Intraday Stock Chart
Today : Wednesday 26 August 2015
Click Here for more Novo Nordisk A S Charts.
More NVO MessagesLatest Novo-Nordisk A/S, NVO Messages
NVO PF
TREND1 • Wed Aug 26, 2015 2:06 PM (7 minutes ago)
Inst % Owned = 7%
TREND1 • Wed Aug 26, 2015 2:05 PM (8 minutes ago)
EPS= 10.10
TREND1 • Wed Aug 26, 2015 2:04 PM (9 minutes ago)
NVO D
TREND1 • Wed Aug 26, 2015 2:03 PM (10 minutes ago)
NVO D
TREND1 • Tue Nov 4, 2014 4:33 PM
FROM DEW
TREND1 • Thu Oct 30, 2014 11:25 AM
THANKS
TREND1 • Tue Oct 28, 2014 1:36 PM
Yes—see #msg-107612584.
DewDiligence • Tue Oct 28, 2014 1:02 PM
Was NOV drop due to reaction of SNY
TREND1 • Tue Oct 28, 2014 12:01 PM
NVO D
TREND1 • Sat Oct 25, 2014 3:04 PM
Bookmark With :
Facebook MySpace Twitter Digg Del.icio.us StumbleUpon Reddit Google Bookmarks Newsvine Technorati Furl AIM Slashdot Yahoo
Your Recent History Page 1 of 2
NYSE
NVO
Novo Nordi..
Quote
Chart
Level 2
News
Trades
News
Financials
NASDAQ
AAL
American A..
Quote
Chart
Level 2
News
Trades
News
Financials
NASDAQ
MSFT
Microsoft
Quote
Chart
Level 2
News
Trades
News
Financials
NASDAQ
MNKD
Mannkind C..
Quote
Chart
Level 2
News
Trades
News
Financials
NYSE
PANW
Palo Alto ..
Quote
Chart
Level 2
News
Trades
News
Financials
AMEX
TNA
Direxion S..
Quote
Chart
Level 2
News
Trades
News
Financials
NASDAQ
ZYNE
ZYNERBA PH..
Quote
Chart
Level 2
News
Trades
News
Financials
NASDAQ
NTEC
Intec Phar..
Quote
Chart
Level 2
News
Trades
News
Financials
NASDAQ
GBT
GLOBAL BLO..
Quote
Chart
Level 2
News
Trades
News
Financials
NASDAQ
BNTC
Benitec Bi..
Quote
Chart
Level 2
News
Trades
News
Financials
NASDAQ
AIMT
AIMMUNE TH..
Quote
Chart
Level 2
News
Trades
News
Financials
LSE quotes are live.
All other quotes are delayed by at least 15 minutes unless otherwise stated.
© 2015 InvestorsHub.Com, Inc.
About Investor Relations (OTC:IHUBY)
About Us
Terms of Service
Privacy Policy
Advertise With Us
Investor Relations
Data Accreditations
Disclaimer
Help FAQ
Site Map
Handbook
Q&A Forum
Contact Us
Tutorials
Educational Educational Channel
Stock Market 101
Educational Videos
Investor Help Forum
More iHub on Facebook
iHub on Twitter
iHub iPhone/iPad App
iHub Android App
iHub BlackBerry App
StockWiki
Auditorium
iHub NewsWire
Recent NVO News
- Tesla Resolves Autopilot Lawsuit, JPMorgan Unveils Potential CEO Successors, and More • IH Market News • 04/09/2024 10:39:30 AM
- Walgreens Slashes Annual Profit Forecast; MillerKnoll Nosedives 17% on Bleak 4Q Outlook, and Latest News • IH Market News • 03/28/2024 01:48:04 PM
- Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News • IH Market News • 03/26/2024 11:20:49 AM
- Unilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and More • IH Market News • 03/19/2024 11:33:10 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2024 05:14:09 PM
- Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity • PR Newswire (US) • 03/08/2024 07:57:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/08/2024 07:53:12 PM
- CNOOC Oil Field Discovery in South China Sea, Grifols Surges 18% After KPMG Approval, and Latest News • IH Market News • 03/08/2024 11:19:59 AM
- Tesla Exits Market Top 10, Victoria’s Secret Stock Tumbles 30% on Weak Forecast • IH Market News • 03/07/2024 10:43:17 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 01:29:02 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2024 03:50:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2024 11:38:51 AM
- Cisco Systems Stock Drops 5% Following Restructuring Plan, Berkshire Trims Apple Stake, and Latest News • IH Market News • 02/15/2024 11:34:25 AM
- Cloudflare Skyrockets 26% Pre-Market; Expedia Plunges 14% After CEO Resignation, and More • IH Market News • 02/09/2024 10:51:57 AM
- Arm Achieves Record Revenue, PayPal Shares Plummet by More Than 9%, and Latest Updates • IH Market News • 02/08/2024 11:10:06 AM
- Boeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and More • IH Market News • 02/06/2024 11:14:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 12:01:57 PM
- Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). • Edgar (US Regulatory) • 01/31/2024 11:55:28 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/31/2024 11:51:16 AM
- U.S. Futures Waver Ahead of Fed Decision Amid Mixed Corporate Earnings; Oil Prices Slide • IH Market News • 01/31/2024 11:29:30 AM
- Walmart’s Stock Split, Elon Musk’s Billion-Dollar Package Revoked, and More • IH Market News • 01/31/2024 11:28:17 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 11:27:38 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 05:21:11 PM
- Philips Shares Drop 6% as US Sales Halted Following Agreement on Faulty Sleep Apnea Devices, and more Wall Street Highlights • IH Market News • 01/29/2024 11:09:38 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM